Employees Provident Fund Board

Position in LLY — ELI LILLY & Co

CIK 1600177 Shah Alam, N8

Position in LLY

as of Mar 31, 2026 · filed May 12, 2026 Compact

Position Value

$482,291,516

+$141,517,980 QoQ

Shares Held

524,361

+65.4% QoQ

Ownership

0.056%

of shares outstanding

% of Portfolio

3.69%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2023

13 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Employees Provident Fund Board holds $1,134,862,339 across 8 Drug Manufacturers - General names. LLY ranks #1 (42.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	LLY	ELI LILLY & Co This page	524,361	$482,291,516
2	MRK	Merck & Co., Inc.	1,895,165	$227,969,397
3	BMY	Bristol Myers Squibb Co	2,509,000	$152,170,850
4	BIIB	Biogen Inc.	704,196	$129,100,252
5	GILD	Gilead Sciences, Inc.	346,000	$48,222,020
6	JNJ	Johnson & Johnson	182,381	$44,581,211
7	ABBV	AbbVie Inc.	145,134	$31,565,193
8	AMGN	Amgen Inc	53,892	$18,961,900

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$482,291,516	524,361	+65.4%	Shares	Sole	2026-05-12
2025-12-31	$340,773,536	317,093	-49.0%	Shares	Sole	2026-03-03
2025-09-30	$474,460,105	621,835	+12.5%	Shares	Sole	2026-03-17
2025-06-30	$430,982,648	552,875	+41.8%	Shares	Sole	2026-03-17
2025-03-31	$322,089,207	389,981	+43.0%	Shares	Sole	2026-03-17
2024-12-31	$210,466,500	272,625	+90.7%	Shares	Sole	2026-03-17
2024-09-30	$126,624,746	142,927	-8.0%	Shares	Sole	2026-03-17
2024-06-30	$140,648,972	155,348	+322.1%	Shares	Sole	2026-03-18
2024-03-31	$28,628,928	36,800	-3.0%	Shares	Sole	2026-03-18
2023-12-31	$22,115,984	37,940	-72.0%	Shares	Sole	2026-03-18
2023-09-30	$72,820,862	135,574	+210.4%	Shares	Sole	2026-03-18
2023-06-30	$20,483,639	43,677	+136.9%	Shares	Sole	2026-03-31
2023-03-31	$6,331,634	18,437	—	Shares	Sole	2026-03-18
No filing history on record for this holder in this stock.